Clazakizumab
(Anti-human IL-6 mAb, human IgG1-Kappa; BMS 945429; ALD518)
Catalog No.: PC-Ab1084Not For Human Use, Lab Use Only.
Clazakizumab (ALD518, BMS 945429) a humanized anti–IL-6 mAb, targets human IL-6 with an affinity of 4 pM, binds circulating IL-6 cytokine rather than the IL-6 receptor 10, 11, blocking both classic signaling and trans-signaling. significantly improves disease activity in rheumatoid arthritis (RA). It has also been evaluated for the treatment of non-small cell lung cancer (NSCLC) and patients with head and neck cancer..
Clazakizumab (ALD518, BMS 945429) a humanized anti–IL-6 mAb, targets human IL-6 with an affinity of 4 pM, binds circulating IL-6 cytokine rather than the IL-6 receptor 10, 11, blocking both classic signaling and trans-signaling. significantly improves disease activity in rheumatoid arthritis (RA). It has also been evaluated for the treatment of non-small cell lung cancer (NSCLC) and patients with head and neck cancer.
Physicochemical Properties
M.Wt
Formula
Human IgG1-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
